U.S. markets open in 6 hours 34 minutes
  • S&P Futures

    3,770.75
    -50.50 (-1.32%)
     
  • Dow Futures

    30,664.00
    -335.00 (-1.08%)
     
  • Nasdaq Futures

    11,504.25
    -186.75 (-1.60%)
     
  • Russell 2000 Futures

    1,698.20
    -23.20 (-1.35%)
     
  • Crude Oil

    109.61
    -0.17 (-0.15%)
     
  • Gold

    1,817.60
    +0.10 (+0.01%)
     
  • Silver

    20.75
    +0.01 (+0.03%)
     
  • EUR/USD

    1.0458
    +0.0014 (+0.14%)
     
  • 10-Yr Bond

    3.0930
    0.0000 (0.00%)
     
  • Vix

    28.16
    -0.20 (-0.71%)
     
  • GBP/USD

    1.2139
    +0.0017 (+0.14%)
     
  • USD/JPY

    136.3380
    -0.2070 (-0.15%)
     
  • BTC-USD

    19,486.13
    -522.64 (-2.61%)
     
  • CMC Crypto 200

    418.79
    -20.88 (-4.75%)
     
  • FTSE 100

    7,312.32
    -11.09 (-0.15%)
     
  • Nikkei 225

    26,393.04
    -411.56 (-1.54%)
     

SHAREHOLDER NOTICE: Brodsky & Smith Announces an Investigation of ARYA Sciences Acquisition Corp IV (Nasdaq - ARYD)

  • Oops!
    Something went wrong.
    Please try again later.
  • Oops!
    Something went wrong.
    Please try again later.
·2 min read
In this article:
  • Oops!
    Something went wrong.
    Please try again later.
  • Oops!
    Something went wrong.
    Please try again later.

BALA CYNWYD, PA / ACCESSWIRE / September 29, 2021 / Law office of Brodsky & Smith announces that it is investigating potential claims against the Board of Directors of ARYA Sciences Acquisition Corp IV ("ARYA IV" or the "Company") (NASDAQ:ARYD) for possible breaches of fiduciary duty and other violations of federal and state law in connection with an agreement pursuant to which ARYA IV, a special purpose acquisition company, will combine with the gene therapy business of Amicus Therapeutics, Inc. ("Amicus") (NASDAQ:FOLD), and result in Amicus' gene therapy business becoming Caritas Therapeutics, Inc., ("Caritas"), which will be a publicly-listed company. Under the terms of the agreement, ARYA IV shareholders will retain ownership of 24% of the combined company.

The investigation concerns whether the ARYA IV Board breached its fiduciary duties to shareholders by failing to conduct a fair process, including the dilution of ownership interest in the combined company.
If you own shares of ARYA IV stock and wish to discuss the legal ramifications of the investigation, or have any questions, you may e-mail or call the law office of Brodsky & Smith who will, without obligation or cost to you, attempt to answer your questions. You may contact Jason L. Brodsky, Esquire, or Marc L. Ackerman, Esquire at Brodsky & Smith, Two Bala Plaza, Suite 805, Bala Cynwyd, PA 19004, visit https://www.brodskysmith.com/cases/arya-sciences-acquisition-corp-iv-nasdaq-aryd/, or call toll free 855-576-4847.

Brodsky & Smith is a litigation law firm with extensive expertise representing shareholders throughout the nation in securities and class action lawsuits. The attorneys at Brodsky & Smith have been appointed by numerous courts throughout the country to serve as lead counsel in class actions and have successfully recovered millions of dollars for our clients and shareholders. Attorney advertising. Prior results do not guarantee a similar outcome.

SOURCE: Brodsky & Smith, LLC



View source version on accesswire.com:
https://www.accesswire.com/666164/SHAREHOLDER-NOTICE-Brodsky-Smith-Announces-an-Investigation-of-ARYA-Sciences-Acquisition-Corp-IV-Nasdaq--ARYD